hydroxyurea has been researched along with Chronic Disease in 72 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea usage led to a small, statistically significant reduction in daily pain, analgesic use, and utilization in adults in MSH, corroborating previously shown larger reductions in crises and mortality." | 9.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks." | 9.12 | Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007) |
| "Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 9.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
| "Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated." | 9.08 | Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis." | 7.69 | Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. ( Bartolí, R; Bertrán, X; Castellá, E; Esteve, M; Fernández-Bañares, F; Gassull, MA; Mañé, J; Ojanguren, I, 1996) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 5.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "Hydroxyurea usage led to a small, statistically significant reduction in daily pain, analgesic use, and utilization in adults in MSH, corroborating previously shown larger reductions in crises and mortality." | 5.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks." | 5.12 | Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007) |
| "Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 5.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
| "Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated." | 5.08 | Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998) |
| "An electronic search encompassing MEDLINE, PubMed, Cochrane Library, and Scopus was completed using the following search terms: rheumatoid arthritis; systemic sclerosis; systemic lupus erythematosus; antineutrophil cytoplasmic antibody-associated vasculitis; mixed connective tissue disease; antiphospholipid syndrome; pyoderma gangrenosum; thromboangiitis obliterans; cryoglobulinemia; hydroxyurea; sickle cell; atrophie blanche; livedoid vasculitis; cholesterol emboli; calciphylaxis; antiphospholipid antibodies; prothrombotic; combined with the terms: chronic wound and leg ulcer." | 4.95 | Vasculitic and autoimmune wounds. ( Angra, D; McNish, S; Rahimi, H; Shanmugam, VK, 2017) |
| "Hydroxyurea (HU) has been shown to induce a variety of cutaneous adverse reactions, including severe leg ulcers." | 3.78 | A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma. ( Berger, A; Blumberg, S; Chen, W; McMeeking, A; O'Neill, D; Pastar, I; Ross, F; Stone, T, 2012) |
| "We report three male patients, with duplex confirmed chronic venous disease, who were on treatment with hydroxyurea for chronic myelogenous leukaemia (CML) and polycythemia vera (PV), referred to us for the management of non-healing perimalleolar ulcers of varying durations." | 3.73 | Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls. ( Gupta, K; Jain, V; Nagpal, N, 2005) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis." | 3.69 | Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. ( Bartolí, R; Bertrán, X; Castellá, E; Esteve, M; Fernández-Bañares, F; Gassull, MA; Mañé, J; Ojanguren, I, 1996) |
| " After their base-line blood levels had been assessed, 3 patients with classical rheumatoid arthritis (according to ARA criteria; American Rheumatism Association) received 500 mg of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) daily (in capsules)." | 3.65 | [Effect of naproxen on DNA synthesis and DNA repair of human lymphocytes in in vivo experiments]. ( Tausch, G, 1975) |
| "Leukostasis is a life-threatening complication of high concentrations of circulating leukemic cells, most often myeloblasts." | 2.82 | Hyperleukocytosis and leukostasis in acute and chronic leukemias. ( Macaron, W; Sargsyan, Z; Short, NJ, 2022) |
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | 2.42 | Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "Hydroxyurea was the most commonly used cytoreductive therapy." | 1.46 | Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017) |
| "Hydroxyurea treatment was not related to leukemic transformation." | 1.43 | Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ, 2016) |
| "The chronic inflammatory state in sickle cell anemia (SCA) is associated with several factors such as the following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production of proinflammatory cytokines." | 1.40 | Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype. ( Bandeira, IC; Barbosa, MC; Elias, DB; Freitas, MV; Gonçalves, RP; Querioz, JA; Rocha, LB, 2014) |
| "Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic." | 1.40 | Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. ( Hasselbalch, HC, 2014) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 1.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "Cranial computed tomography revealed subdural hygroma." | 1.35 | Chronic subdural hygroma with thrombocythemia: first case report. ( Kanat, A; Kazdal, H; Yazar, U, 2009) |
| "Chronic hypoxemia is a common manifestation among patients with sickle cell anemia (SCA) who develop chronic lung disease." | 1.35 | Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. ( Aygun, B; Koumbourlis, AC; Singh, SA, 2008) |
| "Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support." | 1.32 | [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004) |
| "We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS)." | 1.31 | Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. ( Flamm, MJ; Murty, VV; Nichols, GL; Rao, PH, 2002) |
| "Philadelphia chromosome-positive chronic myelogenous leukemia was diagnosed in a now 37-year old woman 16 years ago." | 1.30 | Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy. ( Fiegl, M; Jäger, U; Mitterbauer, G; Pirc-Danoewinata, H; Weltermann, A, 1999) |
| "Reaferon is indicated in chronic myeloid leukemia without splenomegaly." | 1.29 | [Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia]. ( Abdulkadyrov, KM; Balashova, VA; Blinov, MN; Glazanova, TV; Gritsaev, SV; Martynkevich, IS; Moiseev, SI; Rukavitsyn, OA; Shcherbakova, EG, 1995) |
| "Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph1+ CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation." | 1.26 | Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. ( Bennett, AJ; Coccia, PF; Edson, JR; Hasegawa, DK; Krivit, W; Nesbit, ME; Ramsay, NK, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (8.33) | 18.7374 |
| 1990's | 19 (26.39) | 18.2507 |
| 2000's | 29 (40.28) | 29.6817 |
| 2010's | 16 (22.22) | 24.3611 |
| 2020's | 2 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Macaron, W | 1 |
| Sargsyan, Z | 1 |
| Short, NJ | 1 |
| Monus, T | 1 |
| Howell, CM | 1 |
| Lee, SE | 1 |
| Farquhar, DR | 1 |
| Adams, KN | 1 |
| Masood, MM | 1 |
| Senior, BA | 1 |
| Thorp, BD | 1 |
| Zanation, AM | 1 |
| Ebert, CS | 1 |
| Liguoro, I | 1 |
| Arigliani, M | 1 |
| Singh, B | 1 |
| Rees, D | 1 |
| Inusa, BPD | 1 |
| Gupta, A | 1 |
| Bandeira, IC | 1 |
| Rocha, LB | 1 |
| Barbosa, MC | 1 |
| Elias, DB | 1 |
| Querioz, JA | 1 |
| Freitas, MV | 1 |
| Gonçalves, RP | 1 |
| Hasselbalch, HC | 3 |
| Antar, A | 1 |
| Ishak, RS | 1 |
| Otrock, ZK | 1 |
| El-Majzoub, N | 1 |
| Ghosn, S | 1 |
| Mahfouz, R | 1 |
| Taher, AT | 1 |
| Chaturvedi, S | 1 |
| DeBaun, MR | 1 |
| Soyer, N | 1 |
| Haznedaroğlu, İC | 1 |
| Cömert, M | 1 |
| Çekdemir, D | 1 |
| Yılmaz, M | 1 |
| Ünal, A | 1 |
| Çağlıyan, G | 1 |
| Bilgir, O | 1 |
| İlhan, O | 1 |
| Özdemirkıran, F | 1 |
| Kaya, E | 1 |
| Şahin, F | 1 |
| Vural, F | 1 |
| Saydam, G | 1 |
| Andıç, N | 1 |
| Ünübol, M | 1 |
| Yağcı, E | 1 |
| Akay, OM | 1 |
| Yavaşoğlu, İ | 1 |
| Kadıköylü, VG | 1 |
| Bolaman, AZ | 1 |
| Ware, RE | 2 |
| de Montalembert, M | 1 |
| Tshilolo, L | 1 |
| Abboud, MR | 1 |
| Shanmugam, VK | 1 |
| Angra, D | 1 |
| Rahimi, H | 1 |
| McNish, S | 1 |
| D'adda, M | 1 |
| Micheletti, M | 1 |
| Drera, M | 1 |
| Ferrari, S | 1 |
| Rossi, G | 1 |
| Thornburg, CD | 1 |
| Dixon, N | 1 |
| Burgett, S | 1 |
| Mortier, NA | 1 |
| Schultz, WH | 1 |
| Zimmerman, SA | 1 |
| Bonner, M | 1 |
| Hardy, KK | 1 |
| Calatroni, A | 1 |
| Larsen, TS | 1 |
| Pallisgaard, N | 1 |
| de Stricker, K | 1 |
| Møller, MB | 1 |
| Lukina, EA | 1 |
| Sysoeva, EP | 1 |
| Kitsenko, EA | 1 |
| Varlamova, EIu | 1 |
| Inozemtseva, MV | 1 |
| Semenova, EA | 2 |
| Nadinskaia, MIu | 1 |
| Ivashkin, VT | 1 |
| Jain, V | 1 |
| Gupta, K | 1 |
| Nagpal, N | 1 |
| Kanat, A | 1 |
| Yazar, U | 1 |
| Kazdal, H | 1 |
| Spivak, JL | 1 |
| Hasselbalch, H | 1 |
| Smith, WR | 1 |
| Ballas, SK | 2 |
| McCarthy, WF | 1 |
| Bauserman, RL | 1 |
| Swerdlow, PS | 1 |
| Steinberg, MH | 1 |
| Waclawiw, MA | 1 |
| Schloemer, N | 1 |
| Lozovatsky, M | 1 |
| McClain, R | 1 |
| Kent, P | 1 |
| Stone, T | 1 |
| Berger, A | 1 |
| Blumberg, S | 1 |
| O'Neill, D | 1 |
| Ross, F | 1 |
| McMeeking, A | 1 |
| Chen, W | 1 |
| Pastar, I | 1 |
| Prochorec-Sobieszek, M | 1 |
| Nasiłowska-Adamska, B | 1 |
| Borg, K | 1 |
| Kopeć, I | 1 |
| Kos-Zakrzewska, K | 1 |
| Juszczyński, P | 1 |
| Warzocha, K | 1 |
| da Silva, NG | 1 |
| Sampaio, SC | 1 |
| Gonçalves, LR | 1 |
| Bruchova, H | 1 |
| Borovanova, T | 1 |
| Klamova, H | 1 |
| Brdicka, R | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Girgis, RE | 1 |
| Qureshi, MA | 1 |
| Abrams, J | 1 |
| Swerdlow, P | 1 |
| Jeng, MR | 1 |
| Rieman, MD | 1 |
| Naidu, PE | 1 |
| Kaste, SC | 1 |
| Jenkins, JJ | 1 |
| Serjeant, G | 1 |
| Wang, WC | 1 |
| Nielsen, I | 1 |
| Au, WY | 1 |
| Hung, KN | 1 |
| Loong, F | 1 |
| Ma, SK | 1 |
| Lengfelder, E | 1 |
| Berger, U | 1 |
| Reiter, A | 1 |
| Hochhaus, A | 1 |
| Hehlmann, R | 1 |
| Thiele, J | 1 |
| Kvasnicka, HM | 1 |
| Schmitt-Gräff, A | 1 |
| Hülsemann, R | 1 |
| Diehl, V | 1 |
| Geraminejad, PA | 1 |
| Walling, HW | 1 |
| Swick, BL | 1 |
| Sontheimer, RD | 1 |
| Rukavitsyn, OA | 2 |
| Pop, VP | 1 |
| Seriakov, AP | 1 |
| Charlanne, H | 1 |
| Prin, L | 1 |
| Cesar, JM | 1 |
| Cabello, P | 1 |
| Ferro, T | 1 |
| Navarro, JL | 1 |
| Lode, HN | 1 |
| Krings, G | 1 |
| Schulze-Neick, I | 1 |
| Dähmlow, S | 1 |
| Schroeder, U | 1 |
| Bonnet, R | 1 |
| DaPalma, J | 1 |
| Luck, W | 1 |
| Strauss, G | 1 |
| Berger, F | 1 |
| Gaedicke, G | 1 |
| Nelson, H | 1 |
| Kemp, J | 1 |
| Berger, W | 1 |
| Corren, J | 1 |
| Casale, T | 1 |
| Dube, L | 1 |
| Walton-Bowen, K | 2 |
| LaVallee, N | 1 |
| Stepanians, M | 1 |
| Watkins, PB | 1 |
| Dube, LM | 2 |
| Cameron, CM | 1 |
| Kasten, LE | 1 |
| Cervantes, F | 1 |
| Dahabreh, IJ | 1 |
| Giannouli, S | 1 |
| Zoi, C | 1 |
| Zoi, K | 1 |
| Loukopoulos, D | 1 |
| Voulgarelis, M | 1 |
| Singh, SA | 1 |
| Koumbourlis, AC | 1 |
| Aygun, B | 1 |
| Hasegawa, DK | 1 |
| Bennett, AJ | 1 |
| Coccia, PF | 1 |
| Ramsay, NK | 1 |
| Nesbit, ME | 1 |
| Krivit, W | 1 |
| Edson, JR | 1 |
| Carmignani, G | 1 |
| Belgrano, E | 1 |
| Puppo, P | 1 |
| Cichero, A | 1 |
| Giuliani, L | 1 |
| Abdulkadyrov, KM | 1 |
| Moiseev, SI | 1 |
| Shcherbakova, EG | 1 |
| Balashova, VA | 1 |
| Glazanova, TV | 1 |
| Martynkevich, IS | 1 |
| Gritsaev, SV | 1 |
| Blinov, MN | 1 |
| Leber, B | 1 |
| Walker, IR | 1 |
| Rodriguez, A | 1 |
| McBride, JA | 1 |
| Carter, R | 1 |
| Brain, MC | 1 |
| Demidova, AV | 1 |
| Tura, S | 1 |
| Nickerson-Nutter, CL | 1 |
| Medvedeff, ED | 1 |
| Cortes, J | 1 |
| Kantarjian, H | 1 |
| O'Brien, S | 1 |
| Robertson, LE | 1 |
| Pierce, S | 1 |
| Talpaz, M | 1 |
| Martin, MJ | 1 |
| Motilva, V | 1 |
| Luque, MI | 1 |
| De La Lastra, CA | 1 |
| Khoroshko, ND | 1 |
| Turkina, AG | 1 |
| Zhuravlev, VS | 1 |
| Sokolova, MA | 1 |
| Mikhaĭlova, IN | 1 |
| Zakharova, AV | 1 |
| Domracheva, EV | 1 |
| Bertrán, X | 1 |
| Mañé, J | 1 |
| Fernández-Bañares, F | 1 |
| Castellá, E | 1 |
| Bartolí, R | 1 |
| Ojanguren, I | 1 |
| Esteve, M | 1 |
| Gassull, MA | 1 |
| Spector, S | 1 |
| Tan, RA | 1 |
| Vélez, A | 1 |
| López-Rubio, F | 1 |
| Moreno, JC | 1 |
| Ellis, MH | 1 |
| Lazarus, SC | 1 |
| Lee, T | 1 |
| Kemp, JP | 1 |
| Wenzel, S | 1 |
| Ochs, RF | 1 |
| Carpentier, PJ | 1 |
| Lancaster, JF | 1 |
| Fiegl, M | 1 |
| Mitterbauer, G | 1 |
| Weltermann, A | 1 |
| Pirc-Danoewinata, H | 1 |
| Jäger, U | 1 |
| Tefferi, A | 1 |
| Solberg, LA | 1 |
| Silverstein, MN | 1 |
| Navarra, P | 1 |
| Aloe-Spiriti, MA | 1 |
| Boccarini, F | 1 |
| Montefusco, E | 1 |
| Latagliata, R | 1 |
| Preziosi, P | 1 |
| Petti, MC | 1 |
| Gramvussakis, S | 1 |
| George, SA | 1 |
| Chies, JA | 1 |
| Nardi, NB | 1 |
| Flamm, MJ | 1 |
| Murty, VV | 1 |
| Rao, PH | 1 |
| Nichols, GL | 1 |
| Tausch, G | 1 |
| Perkett, EA | 1 |
| Brigham, KL | 1 |
| Meyrick, B | 1 |
| Löfvenberg, E | 1 |
| Nordenson, I | 1 |
| Wahlin, A | 1 |
| Prandota, J | 1 |
| Lerner, HJ | 1 |
| Beckloff, GL | 1 |
| Godwin, MC | 1 |
| Rosten, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life[NCT04705792] | 40 participants (Anticipated) | Interventional | 2020-01-31 | Recruiting | |||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for hydroxyurea and Chronic Disease
| Article | Year |
|---|---|
Hyperleukocytosis and leukostasis in acute and chronic leukemias.
Topics: Chronic Disease; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Leukost | 2022 |
Current and emerging treatments for sickle cell disease.
Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; | 2019 |
Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antisickling Agents; Bloo | 2016 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Vasculitic and autoimmune wounds.
Topics: Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Sy | 2017 |
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
Topics: Antineoplastic Agents; Chronic Disease; Female; Fertility; Humans; Hydroxyurea; Male; Myeloprolifera | 2011 |
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Ch | 2004 |
[Treatment of hypereosinophilia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzam | 2006 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantati | 2007 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Complications of sickle cell anemia in adults: guidelines for effective management.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Brain Diseases; Chest Pain; Child; Child, Preschool; | 1999 |
A clinical update in polycythemia vera and essential thrombocythemia.
Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal | 2000 |
[Chemotherapy of chronic leukemias].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chronic Disease; Cyclophosphamide; Humans; Hydroxyure | 1974 |
7 trials available for hydroxyurea and Chronic Disease
| Article | Year |
|---|---|
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Body Height; Body Weight; Child, Preschool; Chronic Disease; Cognition; Drug To | 2009 |
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Topics: Activities of Daily Living; Adolescent; Adult; Analgesics; Anemia, Sickle Cell; Chronic Disease; Fem | 2011 |
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non- | 2007 |
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Chemical and Drug Induced Liver In | 2007 |
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Topics: Age Factors; Aged; Antineoplastic Agents; Basophils; Bone Marrow; Chronic Disease; Fatigue; Follow-U | 1996 |
Safety and clinical efficacy of zileuton in patients with chronic asthma.
Topics: Asthma; Chronic Disease; Disease Management; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxyge | 1998 |
A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Chronic Disease; Drug Interactions; Female | 2000 |
52 other studies available for hydroxyurea and Chronic Disease
| Article | Year |
|---|---|
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin | 2019 |
Long-term oxygen therapy in children with sickle cell disease and hypoxaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Child; Chronic Disease; | 2021 |
Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Globins; Case-Control Studies; Chromosomes, Human; Chronic Di | 2014 |
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Topics: Chronic Disease; Comorbidity; Humans; Hydroxyurea; Inflammation; Interferon alpha-2; Interferon-alph | 2014 |
Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chronic Disease; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Skin | 2014 |
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe | 2017 |
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea | 2016 |
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
Topics: Adult; Aged; Blood Platelets; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Female; He | 2008 |
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Topics: Alleles; Chronic Disease; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Mutation; Myeloprolifer | 2009 |
[Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
Topics: Abdomen; Adult; Anticoagulants; Antineoplastic Agents; Chronic Disease; Female; Humans; Hydroxyurea; | 2009 |
Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Humans; Hydroxyurea; Hyperpigmentation; Leukemia, Myel | 2005 |
Chronic subdural hygroma with thrombocythemia: first case report.
Topics: Aged; Chronic Disease; Craniocerebral Trauma; Enzyme Inhibitors; Humans; Hydroxyurea; Male; Subdural | 2009 |
Sustained remission of Chronic Immune Thrombocytopenic Purpura with low dose hydroxyurea.
Topics: Adult; Chronic Disease; Female; Humans; Hydroxyurea; Platelet Count; Purpura, Thrombocytopenic, Idio | 2011 |
A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chronic Disease; Debridement; Female; Humans; Hydro | 2012 |
Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Topics: Antineoplastic Agents; Cell Proliferation; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; C | 2012 |
Inhibitory effect of Crotalus durissus terrificus venom on chronic edema induced by injection of bacillus Calmette-Guérin into the footpad of mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; BCG Vaccine; Chronic Disease; Crotalid Venoms; Cro | 2013 |
Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea.
Topics: Adult; Antimetabolites, Antineoplastic; Chronic Disease; Gene Expression Profiling; Gene Expression | 2002 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Decreased exhaled nitric oxide in sickle cell disease: relationship with chronic lung involvement.
Topics: Adult; Anemia, Sickle Cell; Breath Tests; Chronic Disease; Dyspnea; Female; Hemoglobins; Humans; Hyd | 2003 |
Resolution of chronic hepatic sequestration in a patient with homozygous sickle cell disease receiving hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Chronic Disease; Hepatomegaly; Humans; Hydroxyurea; Male | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
Patients presenting with CNS lesions. Case 3. Sequential myeloproliferative disease and glioblastoma multiforme in a renal transplant recipient.
Topics: Administration, Oral; Brain Neoplasms; Chronic Disease; Diagnosis, Differential; Female; Frontal Lob | 2003 |
[Chronic myeloproliferative diseases. Diagnosis and therapy].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagno | 2003 |
Chronic penile ulceration in a 72-year-old man.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Diagnosis, Differential; Drug Eruptions; Hand Dermatos | 2004 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromo | 2006 |
Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia.
Topics: Adult; Anemia, Hemolytic; Blood Transfusion; Chronic Disease; Follow-Up Studies; Hemoglobins, Abnorm | 2007 |
Hypereosinophilic syndrome: another face of janus?
Topics: Aged; Chronic Disease; Female; Flow Cytometry; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Janu | 2008 |
Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Chronic Disease; Female; Humans; Hydroxyurea; Hypox | 2008 |
Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Blood Transfusion; Bone Marrow Transplantation; Ch | 1980 |
Hydroxyurea in the management of chronic urea-splitting urinary infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Chronic Disease; Drug Therapy, Combination; H | 1980 |
Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas.
Topics: Adult; Anemia, Sickle Cell; Cell Adhesion; Chronic Disease; Endothelium, Vascular; Erythrocytes; Ery | 1995 |
[Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].
Topics: Adult; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 1995 |
Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.
Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Combined Modality Therapy; Dermatomyositis; Fem | 1993 |
[Hydroxyurea in the treatment of erythremia].
Topics: Adult; Aged; Chronic Disease; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Middle Aged; Polyc | 1993 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chronic Disease; Disease | 1996 |
Aggravating process induced by indomethacin on chronic gastric lesion in rat. Role of polymorphonuclear leucocytes.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Hydroxyurea; Indomethacin | 1995 |
[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis; Co | 1996 |
Zileuton for asthma.
Topics: Adolescent; Adult; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Dr | 1997 |
Antileukotrienes in chronic urticaria.
Topics: Adult; Chronic Disease; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Male; Phenylcarbamate | 1998 |
Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis.
Topics: Antineoplastic Agents; Chronic Disease; Dermatomyositis; Drug Eruptions; Hand Dermatoses; Humans; Hy | 1998 |
Successful treatment of chronic urticaria with leukotriene antagonists.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Controlled Clinical Trials | 1998 |
Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Cytogenetics; Female; Humans; Hydroxyurea; | 1999 |
Chronic actinic dermatitis (photosensitivity dermatitis/actinic reticuloid syndrome): beneficial effect from hydroxyurea.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug Combinations; Humans; Hydroxyurea; Ma | 2000 |
Sickle cell disease: a chronic inflammatory condition.
Topics: Anemia, Sickle Cell; Animals; Chronic Disease; Humans; Hydroxyurea; Inflammation; Mice; Mice, Transg | 2001 |
Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Cell Differentiation; Chronic Disease; Female; Humans; Hy | 2002 |
[Effect of naproxen on DNA synthesis and DNA repair of human lymphocytes in in vivo experiments].
Topics: Arthritis, Rheumatoid; Chronic Disease; Cobalt Radioisotopes; DNA; DNA Repair; Humans; Hydroxyurea; | 1975 |
Granulocyte depletion attenuates sustained pulmonary hypertension and increased pulmonary vasoreactivity caused by continuous air embolization in sheep.
Topics: Animals; Chronic Disease; Embolism, Air; Granulocytes; Hydroxyurea; Hypertension, Pulmonary; Lung; L | 1990 |
Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chronic Disease; Female; Humans; Hydroxyurea | 1990 |
Phase II study of hydroxyurea administered intermittently in malignant melanoma.
Topics: Adult; Aged; Chronic Disease; Female; Humans; Hydroxyurea; Leukocyte Count; Leukopenia; Male; Melano | 1970 |
Hydroxyurea: a new antimetabolite in the treatment of psoriasis.
Topics: Adolescent; Adult; Blood Cell Count; Blood Platelets; Chronic Disease; Female; Hemoglobinometry; Hum | 1971 |